+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Brazilian Pharmaceutical Market Set To Grow To $41bn By 2022

13 August 2018
Pharma

Visiongain’ has launched a new pharma report Brazilian Pharmaceutical Market Outlook 2017-2027: Originator, Generic, OTC, CNS, Cardiovascular, Gastrointestinal, Metabolic, Oncology, Infectious Diseases, Domestic Manufacturers and International Drug Companies

Brazil’s pharmaceutical market is the eighth largest in the world, and is growing at a faster rate than many of the markets in developed countries. Between 2005 and 2013 it experienced double digit growth rates, and the value of the market tripled. Despite current economic challenges, it is set to continue its expansion well into the 2020s, but at lower growth rates. Growth is being driven by a range of factors including a booming generic drugs market, an underlying shift towards chronic diseases, growing affluence in the country, and a government which aims to increase the population’s access to drugs by making numerous technology transfer deals with multinational companies.

The lead analyst of the report commented “While unmet medical needs present an important opportunity in many areas of the Brazilian market, the oncology and diabetes segments are particularly notable. Brazil has the fifth highest number of diabetes patients in the world while cancer has historically gone unaddressed by the healthcare system. SUS is now facilitating easier access to oncology drugs, thus there is an opportunity for growth.

The Brazilian government is pushing towards technology transfer. Technology transfer is likely to galvanise the nation’s domestic pharmaceutical industry as well as saving the SUS money, but it remains to be seen whether indigenous Brazilian companies will fulfil the government’s ambitions by becoming significant originators of pharmaceutical products and technology platforms.”

Leading companies featured in the report include Sanofi/Medley, EMS, Hypermarcas, Novartis, Eurofarma, Aché, Roche, Merck & Co., Pfizer, Takeda.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2024-2034

The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.

20 February 2024

Read

Visiongain Publishes Biobanking Market Report 2024-2034

The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.

19 February 2024

Read

Visiongain Publishes Dermatological Drugs Market Report 2024-2034

The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.

13 February 2024

Read

Visiongain Publishes Allergic Rhinitis Drugs Market Report 2024-2034

The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.

12 February 2024

Read